

a1 32. A diagnostic kit according to claim 28, wherein said means for disrupting red blood cells is a means for lysing red blood cells.

33. A diagnostic kit according to claim 28, which is suitable for near-patient testing.

---

REMARKS

Attached Claims 1-33 are submitted herewith in place of the claims that were included with the original International Application as filed, and represent revisions to such claims so as to place them in greater conformity with U.S. practice and claim format. The substance of the attached claims is commensurate in scope with that of the Application as filed, and merely seeks to better conform with the requirements for claims that are imposed under the U.S. Patent Laws.


Specifically, the above amendment is primarily taken from the claims that were originally submitted with the Patent Cooperation Treaty Application on filing, and makes certain amendments thereto, so that the resulting claims should be considered in place of those claims that were amended during the examination phase of the pendency of the International Application.

In all of the respects, the Application as filed is believed to be in proper form, and prompt and favorable processing before the U.S. Patent and Trademark Office is accordingly courteously solicited.

PATENT  
2602-1-001

Entry of the foregoing amendments and early and favorable processing in the National  
Phase before the United States Patent and Trademark Office is courteously solicited.

Respectfully submitted,



DAVID A. JACKSON  
Attorney for Applicant(s)  
Registration No. 26,742

KLAUBER & JACKSON  
411 Hackensack Avenue  
Hackensack, NJ 07601  
(201) 487-5800

09/26/2007 09:56:50